Beam Therapeutics Inc.BEAM

NasdaqHealthcareBiological Products, (No Diagnostic Substances)
Price (close)
$24.27
Market cap
$2.5B
P/E
—
Revenue (TTM)
$156.0M
Net income
-$85.4M
Dividend yield
—
1-year total return
5.1%
Net margin
-54.7%
Revenue growth
158.9%
Debt / equity
0.09x

What Beam Therapeutics Inc. does.

No business description on file yet.

Revenue and profit, by fiscal year.

Fiscal year202020212022202320242025
Revenue$24,000$51.8M$60.9M$377.7M$63.5M$139.7M
Net income-$194.6M-$370.6M-$289.1M-$132.5M-$376.7M-$80.0M
Free cash flow-$112.1M-$113.1M-$26.4M-$182.9M-$356.2M-$360.0M

More on BEAM.

Figures from Beam Therapeutics Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.